5332W-12 Continued Access to PREVAIL (CAP2)

Continued Access to PREVAIL (CAP2)

Type of Study
Heart & Vascular - Interventional Cardiology Trials
Short Description

This study aims to provide additional information about the safety and efficacy of the WATCHMAN Left Atrial Appendage Closure Technology

Status
Open
Principal Investigator
Mark Reisman, MD
Eligibility Notes

Men and women 18 years of age or older, who have documented paroxysmal, persistent, or permanent nonvalvular atrial fibrillation, and are eligible for long-term warfarin therapy, but do not require long-term warfarin therapy.

Contact Name
Stephen Lubatti and Inger Rasmussen
Phone
206-215-6573
Alternate Phone
206-215-3989
Email
stephen.lubatti@swedish.org
Alternate Email
inger.rasmussen@swedish.org